> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OK’s Bausch’s ClearVisc Viscosurgical Device
- URL: https://www.fdaweb.com/fda-oks-bauschs-clearvisc-viscosurgical-device/
- Published: 2021-04-07T12:00:00.000Z
- Updated: 2026-09-14T16:53:57.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5149064

FDA has approved Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. OVDs aid in cataract extraction and intraocular lens (IOL) implantation by creating and maintaining space, aiding in tissue manipulation, enhancing visualization, and protecting the corneal endothelium and other intraocular tissues, the company says. OVDs may also be used to coat IOLs and instruments during cataract surgery.  

ClearVisc contains Sorbitol, a chemical agent that has been shown in a laboratory study to deliver superior free radical protection compared to other dispersive OVDs, according to Bausch + Lomb. “Free radicals form as a result of chemical reactions caused during phacoemulsification, irrigation/aspiration and as part of the insertion and removal of instruments and implants,” it says. “Free radicals can contribute to corneal damage and possible decompensation, which can lead to post-surgical complications such as a cloudy cornea. ClearVisc helps provide physical protection of the cornea from thermal and mechanical damage as well as chemical protection from damaging free radicals.”

Approval was based on data from a 372-subject clinical study demonstrated ClearVisc’s non-inferiority to Alcon’s Viscoat, according to the company. Additionally, it says no serious adverse events were seen with ClearVisc eye surgeries.